Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
CytoMed Therapeutics Limited (NASDAQ: GDTC)
GDTC Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-16.10%
Analyst Rating:
NOT AVAILABLE
Analyst Forecast (1yr):
NOT AVAILABLE
GDTC Stock Analysis
GDTC
PE Ratio:
GDTC
PEG Ratio:
Not Available
GDTC
Forward EPS Growth (12 month):
0.00%
GDTC
PS Ratio:
55.1
GDTC
PSG Ratio:
Not Available
GDTC
Forward Revenue Growth (12 month):
0.00%
GDTC Articles
No data was found